|Dose/Strength (ex. 1 mg or 1ml)||As per prescription|
|Melting Point||1050C to 1100C|
|Loss on drying||Not more than 0.5 %|
|Chemical Name||1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-pheny|
|Appearance||Light yellow crystalline powder|
|Solubility||Practically insoluble in water, Sparingly soluble in ethanol|
|Heavy Metals||Not more than 10 ppm|
|Ignited residue (Sulphated Ash)||Not more than 0.1 % w/w|
|Assay ( On Dried Basis)||Not less than 99.0% and not more than 102.0%.|
|Min. Order Quantity||50 Kilogram|
Chemical Name : 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester.
Physical & Chemical Properties : Light Yellow crystalline powder, Practically insoluble in water, Sparingly soluble in ethanol
USE : Cilnidipine (INN) is a calcium channel blocker. Cilnidipine is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. Compared with other calcium antagonists. cilnidipine can act on the N-type calcium channel that existing sympathetic nerve end besides acting on L-type calcium channel that similar to most of the calcium antagonists. Cilnidipine is approved for use in Japan, China,India, Korea and some European countries.
Related Substances (by HPLC) :
Residual solvent :
Particle Size :